KRAS
Boehringer and Lupin team up to battle KRAS-driven cancers in $700m+ deal
September 5, 2019Research and Development, Sales and Marketing Boehringer Ingelheim, Cancer, KRAS, Lupin, collaboration, pharma
Boehringer Ingelheim is set to join forces with Lupin after the pair sealed a partnership agreement to develop, license, and …
Amgen’s novel KRAS inhibitor monotherapy shows promise at Phase 1 in advanced solid tumours
June 4, 2019Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, KRAS
Amgen has unveiled the first clinical data for its investigational KRAS inhibitor AMG 510, the first such therapy to reach …
AZ secures rights from Ionis for first-ever antisense KRAS cancer drug in $165m deal
December 19, 2016Research and Development, Sales and Marketing AstraZeneca, Ionis, KRAS
AstraZeneca has paid a $28 million milestone payment in its partnership with Ionis Pharmaceuticals over the licensing rights to anticancer …
FDA approves Bayer’s Stivarga
October 1, 2012Research and Development, Sales and Marketing Bayer, FDA, KRAS, Roche, Stivarga, avastin
The FDA has approved Bayer HealthCare’s oncology pill Stivarga to treat patients with metastatic colorectal cancer (mCRC) whose disease has …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
